518070-19-4 Usage
Uses
Used in Pharmaceutical Industry:
3-Fluoro-5-methylbenzoic acid is used as an intermediate in the synthesis of five-membered heterocyclic compounds, which are known as mGluR5 receptor antagonists. These antagonists play a crucial role in the development of medications targeting various neurological and psychiatric disorders, such as anxiety, depression, and schizophrenia. 3-FLUORO-5-METHYLBENZOIC ACID's unique structure allows for the creation of potent and selective mGluR5 antagonists, making it a valuable component in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 518070-19-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,8,0,7 and 0 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 518070-19:
(8*5)+(7*1)+(6*8)+(5*0)+(4*7)+(3*0)+(2*1)+(1*9)=134
134 % 10 = 4
So 518070-19-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H6FN3O/c9-5-2-1-3-6(10)7(5)8-11-4-13-12-8/h1-4H,10H2
518070-19-4Relevant articles and documents
Effective palladium-catalyzed hydroxycarbonylation of aryl halides with substoichiometric carbon monoxide
Korsager, Signe,Taaning, Rolf H.,Skrydstrup, Troels
supporting information, p. 2891 - 2894 (2013/04/10)
A protocol for the Pd-catalyzed hydroxycarbonylation of aryl iodides, bromides, and chlorides has been developed using only 1-5 mol % of CO, corresponding to a pCO as low as 0.1 bar. Potassium formate is the only stoichiometric reagent, acting as a mildly basic nucleophile and a reservoir of CO. The substoichiometric CO could be delivered to the reaction from an acyl-Pd(II) precatalyst, which provides both the CO and an active catalyst, and thereby obviates the need for handling a toxic gas.
NEW COMPOUNDS
-
Page 100-101, (2010/02/06)
The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
